Views & Analysis
Category : Views & Analysis /
Novartis looks odds on to extend the indications of its CDK4/6 inhibitor Kisqali into early-stage breast cancer, on the back of data from the phase 3 NATALEE trial reporte
In today's fast-paced digital world delivering relevant, valuable content that resonates with your target audience is more important than ever.
Getting the right treatment, to the right patient, at the right time is the backbone of market access.
Coaching has developed into one of the most powerful tools in a fast-changing pharmaceutical sector.
The demand for high-calibre, sharply-focussed clinical knowledge and data is increasing as HCPs streamline and recalibrate their engagements with the pharmaceutical sector.
The first commercial TIL therapy is brewing at Iovance, along with various clinical readouts which are set to come to fruition in 2023, along with the 5th TIL Therapies Summit whic
Get in-depth news, opinions and features on pharma and healthcare sent straight to your inbox